Related Experiment Video
Updated: Jul 8, 2026
09:37
Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
Published on: August 1, 2018
Hemodynamic alterations in liver cirrhosis.
Giorgio La Villa1, Paolo Gentilini
1Dipartimento di Medicina Interna, University of Firenze, School of Medicine, Firenze, Italy.
Molecular Aspects of Medicine
|January 8, 2008
Summary
Portal hypertension in cirrhosis causes a hyperdynamic circulatory syndrome. Bacterial translocation from the gut may trigger splanchnic vasodilation via factors like nitric oxide.
Area of Science:
- Cardiovascular Medicine
- Gastroenterology
- Hepatology
Background:
- Portal hypertension in cirrhotic patients often presents with a hyperdynamic circulatory syndrome.
- This syndrome is characterized by high cardiac output, reduced systemic vascular resistance, and low arterial pressure.
- The underlying mechanisms of splanchnic vasodilation, a key feature, remain incompletely understood.
Purpose of the Study:
- To explore the mechanisms contributing to splanchnic vasodilation in cirrhotic patients with portal hypertension.
- To investigate the role of intestinal bacterial translocation and its products in this process.
Main Methods:
- The study focuses on a favored hypothesis involving bacterial translocation.
- It examines the release of vasodilating factors such as nitric oxide and carbon monoxide.
Main Results:
- Splanchnic vasodilation is a primary driver of the hyperdynamic circulatory syndrome in cirrhosis.
- Translocation of intestinal bacteria or their products (e.g., endotoxin) is hypothesized to induce local release of vasodilators.
- This release involves factors including nitric oxide and carbon monoxide.
Conclusions:
- Bacterial translocation from the intestine is a leading hypothesis for splanchnic vasodilation in portal hypertension.
- This translocation may lead to the local production of vasodilating mediators, contributing to the hyperdynamic state.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...